Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab

Research output: Contribution to journalAbstractpeer-review


  • Suresh Ramalingam
  • Rina Hui
  • Leena Gandhi
  • Enric Carcereny
  • Enriqueta Felip
  • Myung-Ju Ahn
  • Joseph P Eder
  • Ani S Balmanoukian
  • Natasha Leighl
  • Charu Aggarwal
  • Leora Horn
  • Amita Patnaik
  • Matthew Gubens
  • Matthew Hellmann
  • Jean-Charles Soria
  • Gregory M Lubiniecki
  • Jin Zhang
  • Bilal Piperdi
  • Edward B Garon

Colleges, School and Institutes

External organisations

  • Winship Cancer Institute of Emory University, Atlanta/GA/UNITED STATES OF AMERICA.
  • Westmead Hospital and the University of Sydney
  • Dana-Farber Cancer Institute
  • Catalan Institute of Oncology Badalona, Badalona/SPAIN.
  • Hospital Universitari Vall d'Hebron
  • Samsung Medical Center, Seoul/KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF.
  • Yale University
  • The Angeles Clinic and Research Institute, Los Angeles/UNITED STATES OF AMERICA.
  • University Health Network
  • University of Pennsylvania
  • Vanderbilt-Ingram Cancer Center
  • South Texas Accelerated Research Therapeutics, San Antonio/TX/UNITED STATES OF AMERICA.
  • University of California, San Francisco
  • Memorial Sloan Kettering Cancer Center
  • Université Paris Sud
  • Merck & Co., Inc., Kenilworth/NJ/UNITED STATES OF AMERICA.
  • Merck & Co., Inc., Kenilworth/UNITED STATES OF AMERICA.
  • University of California


Original languageEnglish
Article numberP2.39
Pages (from-to)S241-S242
JournalJournal of Thoracic Oncology
Issue number10 (Supplement)
Early online date22 Sep 2016
Publication statusPublished - Oct 2016
EventIASLC 7th Latin American Conference on Lung Cancer - Panama City, Panama, United States
Duration: 25 Aug 201627 Aug 2016


  • Advanced non-small cell lung cancer, PD-1 inhibition, Pembrolizumab, PD-L1

Sustainable Development Goals